Healthcare provider profile · identity verified

Randy Allen Beddoe, MD

Family Practice · HANFORD, CA · NPI 1740267426

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	320	107
Lisinopril	Lisinopril	192	62
Levothyroxine Sodium	Levothyroxine Sodium	184	46
Amlodipine Besylate	Amlodipine Besylate	169	60
Tamsulosin Hcl	Tamsulosin Hcl	115	33
Losartan Potassium	Losartan Potassium	109	35
Metformin Hcl	Metformin Hcl	108	40
Carvedilol	Carvedilol	86	26
Jardiance	Empagliflozin	84	22
Omeprazole	Omeprazole	81	27
Metoprolol Succinate	Metoprolol Succinate	73	20
Rosuvastatin Calcium	Rosuvastatin Calcium	71	22
Pantoprazole Sodium	Pantoprazole Sodium	67	16
Albuterol Sulfate Hfa	Albuterol Sulfate	66	25
Simvastatin	Simvastatin	56	20
Hydrochlorothiazide	Hydrochlorothiazide	52	20
Tramadol Hcl	Tramadol Hcl	52	14
Gabapentin	Gabapentin	51	16
Meloxicam	Meloxicam	50	23
Alprazolam	Alprazolam	49	11
Furosemide	Furosemide	47	18
Potassium Chloride	Potassium Chloride	45	12
Clopidogrel	Clopidogrel Bisulfate	44	19
Ezetimibe	Ezetimibe	41	13
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	40	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	36	suppressed
Montelukast Sodium	Montelukast Sodium	35	suppressed
Sertraline Hcl	Sertraline Hcl	34	suppressed
Eliquis	Apixaban	33	suppressed
Fluticasone Propionate	Fluticasone Propionate	33	14
Spironolactone	Spironolactone	32	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	30	12
Metformin Hcl Er	Metformin Hcl	28	11
Allopurinol	Allopurinol	27	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	27	12
Ozempic	Semaglutide	27	suppressed
Alendronate Sodium	Alendronate Sodium	26	suppressed
Atenolol	Atenolol	26	suppressed
Clonidine Hcl	Clonidine Hcl	26	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	26	suppressed
Donepezil Hcl	Donepezil Hcl	25	suppressed
Xanax	Alprazolam	25	suppressed
Benazepril Hcl	Benazepril Hcl	22	suppressed
Famotidine	Famotidine	22	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	22	suppressed
Naproxen	Naproxen	22	suppressed
Chlorthalidone	Chlorthalidone	21	suppressed
Pravastatin Sodium	Pravastatin Sodium	21	suppressed
Trazodone Hcl	Trazodone Hcl	21	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	20	suppressed
Ibuprofen	Ibuprofen	20	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	20	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	19	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	19	12
Ropinirole Hcl	Ropinirole Hcl	19	suppressed
Diclofenac Sodium	Diclofenac Sodium	18	14
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	18	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	17	suppressed
Azithromycin	Azithromycin	17	13
Duloxetine Hcl	Duloxetine Hcl	17	suppressed
Mounjaro	Tirzepatide	17	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	16	suppressed
Buspirone Hcl	Buspirone Hcl	15	suppressed
Januvia	Sitagliptin Phosphate	15	suppressed
Lorazepam	Lorazepam	15	suppressed
Ventolin Hfa	Albuterol Sulfate	15	suppressed
Carbidopa-Levodopa Er	Carbidopa/Levodopa	14	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	14	suppressed
Farxiga	Dapagliflozin Propanediol	14	suppressed
Finasteride	Finasteride	14	suppressed
Ketoconazole	Ketoconazole	14	suppressed
Memantine Hcl	Memantine Hcl	14	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	14	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	14	suppressed
Digoxin	Digoxin	13	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	13	suppressed
Hydrocodone-Ibuprofen	Hydrocodone/Ibuprofen	13	suppressed
Glipizide Er	Glipizide	12	suppressed
Levetiracetam	Levetiracetam	12	suppressed
Cephalexin	Cephalexin	11	suppressed
Fluocinonide	Fluocinonide	11	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error